
CHF5074
CAS No. 749269-83-8
CHF5074 ( CHF-5074 | CHF5074 | CHF 5074 | CSP-1103 )
产品货号. M17588 CAS No. 749269-83-8
CHF5074 是一种 γ-分泌酶调节剂,可减少 Aβ42/40 分泌(IC50:3.6/18.4 μM)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥356 | 有现货 |
![]() ![]() |
5MG | ¥583 | 有现货 |
![]() ![]() |
10MG | ¥915 | 有现货 |
![]() ![]() |
25MG | ¥1847 | 有现货 |
![]() ![]() |
50MG | ¥2940 | 有现货 |
![]() ![]() |
100MG | ¥4431 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称CHF5074
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CHF5074 是一种 γ-分泌酶调节剂,可减少 Aβ42/40 分泌(IC50:3.6/18.4 μM)。
-
产品描述CHF-5074, also known as CSP-1103, is a γ-secretase modulator. CHF-5074 reduces Aβ42 and Aβ40 secretion, with an IC50 of 3.6 and 18.4 μM respectively. CHF5074 reduces brain beta-Amyloid pathology in a transgenic mouse model of Alzheimer's Disease without causing peripheral toxicity. CHF5074 is a non-steroidal anti-inflammatory derivative holding disease-modifying potential for the treatment of Alzheimer's disease.
-
体外实验——
-
体内实验Animal Model:Male and female Tg2576 transgenic mice expressing Swedish mutated form of human APP (APPswe)Dosage:375 ppm Administration:Oral administration; 375 ppm in the diet for 17 weeks Result:Reduced total brain Aβ42 and Aβ40 levels, and brain plaque burden in aged Tg2576 mice. Caused no COX-mediated toxic effects in the gastrointestinal tract and Notch-mediated cell differentiation abnormalities in the ileum.
-
同义词CHF-5074 | CHF5074 | CHF 5074 | CSP-1103
-
通路Angiogenesis
-
靶点EGFR
-
受体Beta Amyloid| γ secretase
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number749269-83-8
-
分子量325.16
-
分子式C16H11Cl2FO2
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 37 mg/mL; 113.79 mM
-
SMILESClc1cc(c2c(F)cc(C3(CC3)C(=O)O)cc2)ccc1Cl
-
化学全称1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Imbimbo BP, et al. J Pharmacol Exp Ther. 2007 Dec;323(3):822-30. 2. Ronsisvalle N, et al. Curr Alzheimer Res. 2014;11(7):714-24.